Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

If you've ever wondered how to seamlessly transition from R&D to process development, this is your golden ticket. Uncover practical strategies and expert advice that can be your compass through the intricate landscape of mastering CMC development.

Uncover the challenges and tactics to seamlessly navigate this critical phase.

1. Conduct Early Developability Assessments: By assessing productivity, aggregation propensity, and manufacturability early on, you can strategically avoid future roadblocks.
2. Use a Platform: A platform approach facilitates swift and cost-effective transitions to clinical trials, reducing pre-proof of concept investment.
3. Bridge the R&D and Process Development Gap: Navigating this intricate phase successfully leads to seamless collaboration, promoting a unified approach and shared understanding among team members.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

Embark on a journey into the intricate world of CMC development with our latest episode, unraveling the challenges that often baffle biotech scientists. The complexity of CMC development is a formidable hurdle, and in this insightful discussion, we delve into strategies to master this critical process.

Key Takeaways:

1. Start Early: Learn how starting CMC development early, even without a complete understanding of your drug, can reduce risks and prepare you better for clinical milestones.
2. Collaborate: CMC development should not work in isolation but integrate insights from diverse teams for a comprehensive drug development strategy.
3. Adopt a Platform Approach: Understand the role of platform processes in speeding up drug development and how they facilitate multiple attempts for cost-efficient progression from discovery to clinical trials, particularly in biologics.

Your journey to mastering CMC development starts here.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

Are you looking for advanced strategies to enhance the quality and efficiency of cell therapy manufacturing processes?

In this episode with Shin Kawamata, CEO of Cyto-Facto Inc., we dive into the transformative power of digitization in cell therapy manufacturing and explore strategies to enhance efficiency and reduce costs.

Actionable Takeaways:

1. Initiate Digital Transformation: Take the first step toward transforming your manufacturing processes by incorporating robust data business practices, ensuring a maturation of the cell therapy industry.
2. Leverage AI and Metabolome Sensors: Discover actionable insights into harnessing the power of AI for navigating cell therapy complexities. Implement metabolome sensors to actively monitor cell culture, gathering essential data for quality control and elevating your therapy development strategies.
3. Cultivate Collaborative Ecosystems: Shin shares practical insights into building comprehensive ecosystems and collaborating with various stakeholders.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

• LinkedIn: www.linkedin.com/in/shin-kawamata-84647579
• Website: www.cytofacto.com/eng

Get Cell and Gene Therapy Training:

• Shin Kawamata's offer: The Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory: https://www.isctglobal.org/resources/training-programs/workforce-development-in-biomanufacturing401/workforce-development-in-biomanufacturing
• Learn more about the upcoming Cell and Gene Therapy Training program for the Asia Pacific region: contact David at [email protected]

Support the show

Are the escalating costs and intricate technical hurdles of cell therapy development causing you stress?

Tune into this insightful podcast episode featuring Shin Kawamata, CEO of Cyto-Facto Inc. in Kobe, Japan, who shares his expertise and innovative solutions to these pressing issues in the cell therapy industry.

Discover how to streamline your manufacturing processes, reduce costs, and enhance product quality, transforming the way you approach cell therapy development.

Key Takeaways:

1. Revolutionize Cell Manufacturing: Shin outlines how Cyto-Facto is pioneering a new business model, merging public sector support with commercial viability. Learn how this shift can accelerate the growth of the cell therapy industry.
2. Leverage QbD in Living Systems: Discover why Quality by Design (QbD) strategies are imperative for cell therapy manufacturing.
3. Scale Up Efficiently: Shin shares valuable insights on the challenges in scaling up cell therapies and the importance of automation, digitalization, and QbD in streamlining manufacturing processes, reducing costs, and enhancing product quality.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

• LinkedIn: www.linkedin.com/in/shin-kawamata-84647579
• Website: www.cytofacto.com/eng

Get Cell and Gene Therapy Training:

• Shin Kawamata's offer: The Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory: https://www.isctglobal.org/resources/training-programs/workforce-development-in-biomanufacturing401/workforce-development-in-biomanufacturing
• Learn more about the upcoming Cell and Gene Therapy Training program for the Asia Pacific region: contact David at [email protected]

Support the show

Welcome to Part 2 of our conversation with Bernardo Estupiñán Gaisbauer, Principal at Drug Biologics Consulting.

In this insightful episode, we dive into the complex world of taking a molecule from the lab to clinical trials. Our guest shares invaluable insights into outsourcing strategies for biotech companies.

Key Learnings:

• Strategic Outsourcing: Discover when and why outsourcing is crucial for biotech companies, particularly in areas like analytical work and process development. Learn how it can be a game-changer for companies of all sizes.
• Critical Outsourcing Steps: Understand the pivotal role of analytics in confirming lab results and ensuring a robust process. Explore the importance of choosing the right outsourcing partner for scalability, from small bioreactors to larger manufacturing stages.
• Balancing Control and Expertise: Uncover the delicate balance between keeping in-house control and leveraging the expertise of outsourcing partners. Gain insights into finding the sweet spot to achieve process understanding and cost efficiency.

Join us for a deep dive into the outsourcing landscape, unraveling the intricacies of selecting the right partner and ensuring a successful collaboration. Tune in and elevate your biotech game!

Connect with Bernardo Estupiñán Gaisbauer:

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

• Consider Developability and Manufacturability: The success of your biotech asset hinges on developing a scalable process and ensuring cost-effective manufacturing. Assessing these aspects early guides strategic decision-making.
• Start Early: Bernardo stresses the need to consider crucial milestones from the moment you conceive a promising molecule. Avoid costly delays by initiating conversations with potential partners and service providers at the earliest stages.
• Find a Balance for Regulatory Aspects: While regulatory considerations are crucial, Bernardo advises against premature obsession. Prioritize good laboratory and manufacturing practices initially, saving detailed regulatory planning for later stages.

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

In part 2 of this interview with Ioscani, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, we delve into the art and science of accelerating process development through the strategic extraction of valuable insights from data.

Our guest, a seasoned expert in computational modeling, unfolds the intricate dance between quality by design principles and data-driven approaches.

Key takeaways from this insightful conversation include:

• Optimizing with Confidence: Understand the input-output relationships qualitatively and quantitatively. Frame confidence spaces and align them with the design space for robust models.
• Strategic Experimentation: Uncover the fine line between modeling and experimental work. Learn how to use computational models to design optimally informative experiments, saving both time and resources.
• Balancing Act with Data: Navigate the delicate balance between adding value to model development programs and not overwhelming companies with excessive data demands.

Join us as we explore the transformative power of computational models in the biopharma sector, unlocking new possibilities for process optimization and efficiency.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

Join us as we unravel the complexities of computational methods in bioprocessing, featuring cutting-edge research on glycosylation and process development.

Ioscani Jiménez del Val, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, explores the intricacies of creating computational models, closing the loop, and optimizing with numerical methods.

Discover the two broad flavors of modeling – kinetic and metabolic models – and how they contribute to understanding cellular processes in bioreactors.

Key Learnings:

• Closed Loop Optimization: Learn how closing the computational loop enhances model robustness, generating experimental data to refine kinetic parameters.
• Modeling Variety: Explore different computational models, including kinetic models, metabolic models, and the rising trend of data-driven approaches for efficient bioprocess monitoring.
• Hybrid Modeling: Uncover the power of hybrid models, combining mechanistic and data-driven approaches for a comprehensive understanding of your production process.

Experience the journey of innovation as we explore how the revolutionary process of extracting valuable insights from your data is transforming the field of bioprocessing. Tune in now for an enlightening conversation with our esteemed expert guest.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

In part 2, we explore the details of cost reduction in cultivated meat manufacturing, with a focus on two important factors: media and simplified bioreactors.

Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, highlights the strategic importance of selecting the right cells and advocates for a streamlined process that incorporates plant-based structures. This approach offers a cost-effective entry point for supermarkets.

Key Learnings:

• Discover the challenges of adapting adherent media for meat cells in suspension culture.
• Find out the most cost-effective approach that enables competitive pricing of cultivated meat products.
• Understand why the future of cultivated meat lies in niche products, which offer additional options alongside traditional meat and plant-based alternatives.

Don't miss this engaging conversation that unlocks the future of sustainable and innovative meat production.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show

Is bacon without pigs the future? In this episode, join us as Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, unveils the exciting possibilities.

Discover how he overcomes the challenges of production and envisions a future where cultivated steak competes on price. Beat Thalmann provides an insider's perspective on the complexities of cell lines and production processes, exploring the intersection of biopharmaceuticals and cultivated meat.

Explore the innovative techniques companies are adopting, from rethinking bioreactors to recycling media, in their quest to bring affordable and sustainable alternatives to our plates.

You will Learn:

1. Overcoming production challenges: Learn how you can tackle the hurdles in the development and scaling of cultivated meat production processes.
2. Innovative techniques: Discover the cutting-edge approaches being employed by companies in the field, such as reimagining bioreactors and adopting media recycling practices.
3. Strategies for Cost-Effective Scaling: Get a roadmap to achieving cost-effective processes, making cultivated meat a viable and affordable option for the future.

Tune in now to explore the future of bacon, steaks, and more – all without the need for traditional farming. It's a fascinating journey into the world of cultivated meat technology.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show